|
|
 |
|
Viewing report
|
|
|
|
Advances in Biomarkers
Frost & Sullivan, March 2007
This Frost & Sullivan research service titled Advances in Biomarkers provides an overview of emerging technologies and their applications in disease diagnosis, drug discovery and development, personalized medicine etc., along with key drivers, restraints and analysis of trends witnessed in the biomarker industry. In this research, Frost & Sullivan's expert analysts thoroughly examine the following technologies: genomics, proteomics, metabolomics, and systems biology.
This research service is available through our Technical Insights Growth Partnership Services program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new theories tested in hundreds of companies across many industries, Frost & Sullivan has evolved its Growth Partnership Services (GPS) program that provides established and emerging firms with powerful growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth consulting partners by illustrating how key intelligence and strategic research based on defined goals can guide day-to-day behavior and overall company direction. The foundation of Frost & Sullivan's GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximize the potential for growth within a firm’s internal and external environment, Frost & Sullivan consultants can facilitate the creation of strategic programs that deliver improved market success. Frost & Sullivan’s strengths lie in combining strategic understanding with market expertise and applying these with absolute commitment to its clients’ growth
Biomarkers: Creating Milestones in the Development of Clinical Diagnostics and in phases of Drug Discovery
Biomarkers have become key decision tools in the pharmaceutical and diagnostic industries and are also perceived to be an essential tool in drug development by government regulatory agencies. Enormous research is underway to bring to the market biomarker-based screening tests as it is simple, easy-to-use and non-invasive. Prime areas of focus include the early diagnosis of cancer, cardiovascular disorders, and neurodegenerative disorders such Alzheimer's disease and Parkinson's disease. Apart from early diagnosis, biomarkers enable elucidation of drug mechanisms, analysis of the drug efficacy and safety, and characterization of patient populations for clinical trials and clinical trial outcomes.
Advances in techniques for identifying, developing, and validating biomarkers are continuously enhancing the efficiency and productivity of the drug development industry. There are several groups, both commercial and academic, who are actively involved in biomarker discovery. However, only a few of the markers stemming from these projects have been properly validated. 'This lack of independent validation explains the lag phase in biomarker transition from discovery to development as well as a relatively small impact of biomarker research on healthcare,' cites the analyst of this research service. 'Nonetheless, biomarkers, once validated and accepted, can play a vital role in disease diagnosis, phases of drug discovery and development, and medicines tailored to an individual.'
Rapidly Evolving Technology Trends in Biomarker Industry to Revolutionize the Future of Healthcare
The two major technologies that have dominated the technology landscape of the biomarker industry have been genomics and proteomics. A third generation of ‘omics’ or the metabolomics is underway, which takes advantage of biochemical pathway information and holds potential to deliver cost-effective technologies to the market. Systems biology approach to analyse and interpret the vast quantities of information generated from the -omics platform certainly appears poised to take the industry by storm.
'Biomarker discovery, development, and applications call for an integrated outlook as biomarker research consists of many stages with continuous technological progress influencing each of them,' says the analyst. 'With regulatory authorities playing a strong and influential role in biomarker research, a hand-in-hand approach by the entire force including research personnel, investors, venture capitalists, and members of the medical community, can prove instrumental in accomplishing the complete and successful integration of biomarkers into healthcare.'
Customers who bought this item also bought
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Biomarkers - Technologies, Markets and Companies
Biomarkers 2008
Companion Biomarkers in Drug Development
Biomarkers - Advanced Technologies and Global Market (2009-2014)
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Cancer Biomarkers: Players, Products and Prospects (Volume I)
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
Licensing Strategies for Accessing Biomarker Technologies
|
|
|
|
